Stemline Therapeutics (STML) 10-Q2014 Q1 Quarterly report

Filed: 15 May 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Good

New words: absolute, apparent, assumption, attack, back, billion, built, calendar, categorized, category, Chemistry, chronic, CMC, compliant, conformity, correlation, deduction, description, disease, Dodd, filer, fortify, fortifying, Frank, GMP, highest, Hodgkin, hypereosinophilic, iii, imiquimod, immunotherapy, instrument, intrinsic, IRC, IRS, iv, Janssen, Johnson, jurisdiction, line, LLS, lymphoma, mission, mitigate, MM, myelomonocytic, myeloproliferative, nonconvertible, optimum, optionee, Oxley, path, PCT, Prepaid, pretax, PRs, ramp, ramped, receptor, reclassified, recover, refractory, relapsed, remission, resource, routinely, short, Society, straight, temporary, toxoid, Unadjusted, unmet, unrealized, version, yearly

Removed: acceleration, accounted, achieved, affecting, aid, amortization, annum, April, assigned, assignment, assumed, Athyrium, average, began, Bergstein, Bulletin, calculate, calculated, cancel, capitalization, Chairman, commenced, consecutive, consideration, consummation, convert, converted, CSL, cumulative, cycle, defer, derive, desired, digit, discount, discounted, dividend, Dr, employment, entity, Eric, evaluate, evaluating, exit, expectation, FASB, feasibility, feature, federally, Finally, fluctuate, framework, group, guideline, Head, headcount, helper, hope, impacting, implied, inaccuracy, incremental, IND, insured, Ivan, leader, light, mandatorily, mark, marked, maximize, measuring, merit, minimize, modification, modified, NB, objective, observed, occurrence, orderly, peer, persuade, pronouncement, quantitative, reached, recognition, redemption, regimen, remeasured, rendered, repayment, representation, representative, requirement, reserved, revalued, Rowinsky, sector, selected, sponsor, standard, timeframe, title, traded, underwriting, updated, vaccine, Vice, warranty, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

STML similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

STATEMENT OF CHIEF ACCOUNTING OFFICER OF
STEMLINE THERAPEUTICS, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Stemline Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, David G. Gionco, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2014	/s/ David G. Gionco
	David G. Gionco
	Chief Accounting Officer
	Principal Financial and Accounting Officer